tbuckley/cabot-search huggingface dataset:
MA12.07 Integrative Transcriptome Analysis of Malignant Pleural Mesothelioma Reveals a Clinically-Relevant Immune-Based Classification
Authors: A. Alay, D. Cordero, E. Aliagas, S. Hijazo-Pechero, V. Moreno, R. Palmero Sánchez, J.C. Ruffinelli, R. Ramos, I. Macia, X. Solé, E. Nadal
Journal: Journal of Thoracic Oncology (2019)
Abstract 16122: G6PD and CYP450 Enzyme Regulate Hematopoietic Stem Cell Biology: Implication to Pulmonary Artery Remodeling in Pulmonary Hypertension
Authors: Ryota Hashimoto, Gregg Lainer, Rubin Tuder, Kurt R Stenmark, Sachin A Gupte
Journal: Circulation (2018)

Introduction: Pulmonary hypertension (PH) is a multi-cellular disease with a high mortality rate. Some studies have incriminated and other studies have exonerated stem cells in the remodeling of pu...
TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia
Authors: Esteban Braggio, J. Jonathan Keats, Xavier Leleu, Ellen Remstein, Scott Van Wier, Victor H Jimenez-Zepeda, Riccardo Valdez, Roelandt Schop, Tammy Price-Troska, Antonio Sacco, Feda Azab, Philip R. Greipp, Morie Gertz, S. Vincent Rajkumar, Marta Chesi, Keith Stewart, Ahmet Dogan, Peter Leif Bergsagel, Irene Ghobrial, Rafael Fonseca
Journal: Blood (2008)
European drug regulator fears return to days of data secrecy
Authors: Rebecca Coombes
Journal: BMJ (2019)

The agency that regulates drugs in Europe is nervously awaiting the outcome of an industry driven court case that aims to curb public access to clinical trial documents.

Two drug companies have argued that the European Medicines Agency (EMA) should stop making public any information on clinical trials that businesses consider commercially confidential. An initial ruling in February 2018 found in the EMA’s favour and said that, in general, clinical study reports should not be considered confidential.

But, in an appeal ruling on 11 September, advocate general Gerard Hogan found that disclosure of the documents would harm the companies’ commercial interests. These cases, taken by Merck and by PTC Therapeutics, are …
EP1.01-42 Is Serum Lymphocyte Count Predictive Biomarker to Identify Lung Cancer Patients Who May Benefit from an Immunotherapy?
Authors: Y.J. Lee, S.Y. Yun, T.Y. Park, D.K. Kim, H.S. Chung, J.K. Lee, E.Y. Heo
Journal: Journal of Thoracic Oncology (2019)
P1.01-90 Update Phase II Results of Early Primary Tumor Stereotactic Body Radiotherapy Combined with First-Line EGFR-TKI in Advanced EGFR Mutated NSCLC
Authors: D. Lv, H. Xu, Y. Meng, W. Wang, X. Wu, F. Kong, H. Yang
Journal: Journal of Thoracic Oncology (2019)
EP1.04-11 Frequency of Microsatellite Instability (MSI) in Brazilian TKI Non-Treatable Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: P. De Marchi, G. Noriz Berardinelli, R. Cavagna, F. De Paula, E. Albino Da Silva, J. Miziara, L. Leal, R. Reis
Journal: Journal of Thoracic Oncology (2019)
P2.09-20 The Possible Clinical Significances of Infiltration of CD8+ Lymphocytes in Non-Small Cell Lung Cancers
Authors: K. Shiomi, M. Ichinoe, S. Jiang, M. Naito, M. Mikubo, Y. Matsui, S. Tamagawa, A. Mitsui, S. Hayashi, Y. Satoh, Y. Matsuo
Journal: Journal of Thoracic Oncology (2019)
P1.14-06 Tissue-Based Molecular and Histologic Landscape of Acquired Resistance to Osimertinib in Patients with EGFR-Mutant Lung Cancers
Authors: A. Schoenfeld, J. Chan, H. Rizvi, R. Somwar, D. Kubota, Y. Daneshbod, J. Chang, M. Offin, M. Arcila, D. Pe'Er, M. Kris, N. Rekhtman, G. Riely, M. Ladanyi, H. Yu
Journal: Journal of Thoracic Oncology (2019)
P2.01-18 ORION: Durvalumab+Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Ahn, Y. Liu, T. Improta, M. Marcovitz, K. Dipiazza, M. Lanasa
Journal: Journal of Thoracic Oncology (2019)
MA15.03 Exploring Digital Pathology-Based Morphological Biomarkers for a Better Patients’ Selection to the Immune Checkpoint Inhibitor of Lung Cancer
Authors: N. Motoi, H. Yoshida, T. Kiyuna, H. Horinouchi, T. Kohno, S. Watanabe, Y. Ohe, A. Ochiai
Journal: Journal of Thoracic Oncology (2019)
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
Authors: Luciana Molinero, Yijin Li, Ching-Wei Chang, Sophia Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol O’Hear, Priti Hegde, Leisha A. Emens
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME) and genomic evolution across sequential therapies in a patient with a 31-year history of TNBC and a complete response (CR) to atezolizumab monotherapy. <h3>Materials and methods</h3> In 1986, the patient had surgery and radiotherapy (XRT) for newly diagnosed TNBC, followed by surgery and adjuvant chemotherapy for two locoregional recurrences. She developed mTNBC in 2009 and was sequentially treated with capecitabine, gemcitabine-carboplatin-iniparib (GCI), XRT and an experimental vaccine. She experienced disease progression (PD) to all these therapies. In 2013, she had a PD-L1 positive tumor and enrolled in a phase 1 atezolizumab monotherapy study (PCD4989g; NCT01375842). She received atezolizumab for 1 year with initial pseudo-progression followed by a partial response. After 1 year without treatment she experienced PD, reinitiated atezolizumab and subsequently achieved CR. Tumor specimens were collected at numerous times between 2008 and 2015 and assessed by immunohistochemistry, RNA-seq and DNA-seq. <h3>Results</h3> TiME biomarkers, including CD8, ICs and PD-L1 on IC, increased after capecitabine and remained high after GCI, XRT and through pseudo-progression on atezolizumab. At PD post-atezolizumab exposure, TiME biomarkers decreased but PD-L1 status remained positive. Immune-related RNA signatures confirmed these findings. TNBC subtyping revealed evolution from luminal androgen receptor (LAR) to basal-like immune activated (BLIA). Genomic profiling showed truncal alterations in <i>RB1</i> and <i>TP53</i>, while the presence of other genomic alterations varied over time. Tumor mutational burden peaked after XRT and declined after atezolizumab exposure. <h3>Conclusions</h3> This case report describes the evolution of TiME and TNBC molecular subtypes/genomics over time with sequential therapies in a TNBC patient with a CR to atezolizumab monotherapy. These data suggest the TiME is pliable and may be manipulated to maximize response to immunotherapy (NCT01375842, https://clinicaltrials.gov/ct2/show/NCT01375842?term=NCT01375842&amp;rank=1).
P1.10-07 Characteristics of Current and Former Smokers Who Acknowledge Their Risk of Lung Cancer: Results from the EDIFICE6 Survey
Authors: S. Couraud, L. Greillier, T. De La Motte Rouge, C. Touboul, C. Lhomel, J. Viguier, F. Eisinger, M. Roupret, J. Morère
Journal: Journal of Thoracic Oncology (2019)
Oligonucleotide Array CGH Studies in Myeloproliferative Neoplasms and Comparison with Conventional Cytogenetic Analysis
Authors: Ayalew Tefferi, Shireen Sirhan, Yi Sun, Terra L. Lasho, Charles A. LeDuc, Christy M. Finke, James Weisberger, Sherri Bale, John Compton, Animesh Pardanani, Erik C. Thorland, Yuriy Shevchenko, Marc D. Grodman, Wendy K. Chung
Journal: Blood (2007)
Letter to the Editor: Glomerular Filtration Rate Assessment in Liver Disease (GRAIL): Are We There Yet?
Authors: Joana Carvão, Luís Jasmins
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. To The Editor: Renal dysfunction is common in liver cirrhosis, and it is associated with poor prognosis. However, we still have major limitations when assessing renal function in patients with cirrhosis. Current available methods are biased and have a tendency to consistently overestimate glomerular filtration rates (GFRs). We read with great interest the article by Asrani et al.1 regarding the development of a GFR model in patients with liver disease, before and after liver transplant (LT), the glomerular filtration rate assessment in liver disease (GRAIL). Indeed, the need for a new mathematical formula for GFR in cirrhosis is of concern. Kalafateli et al. also developed a formula, the Royal Free Hospital Cirrhosis (RFHC) for estimation of GFR in stable patients being evaluated for liver transplantation.2 The RFHC comprises age, sex, creatinine, urea, international normalized ratio, and ascites whereas GRAIL is based on sex, age, ethnicity, creatinine, blood urea nitrogen, and albumin. There are some important differences between the two. First, GRAIL comprises ethnicity, a well‐known factor that affects GFR estimation in the general population.3 Even though these data are well established in the general population, the effect in the population with cirrhosis is still unknown. The RFHC did not include ethnicity, mostly because of type 2 error. Serum albumin levels in GRAIL can be altered because of recent albumin infusions and therefore overestimate GFR. The assessment of ascites in the RFHC poses a problem given that it is a subjective measure. One pitfall for both equations is that a marker for muscle mass estimation was not incorporated. Decreased muscle mass has a great impact on overestimation of kidney function, especially in male patients with cirrhosis, as shown in a recent study.4 Even though, as stated by the researchers, the GRAIL model is skewed to predict lower GFR, it would be interesting to see how this equation would have compared to the RFHC. Further validation studies are required for both formulas; however, we are finally on the path to conceive a better GFR formula in the population with cirrhosis.
P2.04-17 Immune Repertoire Is a Potential Predictive Biomarker for Evaluating the Efficacy of Mutant Neoantigen Specific T Cell Combined with PD1 Antibody
Authors: Q. Song, J. Li, T. Zhang, Z. Zhou, Y. Song, S. Sun, B. Qin, J. Wang, L. Zhang, X. Zhang, D. Wang, M. Chen, J. Li, S. Jiao
Journal: Journal of Thoracic Oncology (2019)
P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma
Authors: A. Januszewski, Y.Z. Zhang, C. Brambilla, W. Chang, U. Laggner, A. Bowman, T. Adefila-Ideozu, I. Vivanco, W. Cookson, M. Moffatt, A. Nicholson, S. Popat, A. Bowcock
Journal: Journal of Thoracic Oncology (2019)
P1.06-10 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Diagnostic/Prognostic Performance and Correlation with Pathological Results
Authors: F. Lococo, O. Rena, F. Torricelli, A. Filice, T. Di Stefano, C. Rapicetta, C. Coruzzi, R. Boldorini, A. Ciarrocchi, A. Versari, M. Paci
Journal: Journal of Thoracic Oncology (2019)
P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC
Authors: C. Kim, L. Xi, C. Cultraro, F. Wei, J. Cheng, A. Shafiei, T. Pham, N. Roper, E. Akoth, C. Strom, M. Tu, W. Liao, D. Chia, C. Morris, A. Rajan, M. Bagheri, G. Jones, D. Wong, M. Raffeld, U. Guha
Journal: Journal of Thoracic Oncology (2019)
Association Between Limited English Proficiency and Revisits and Readmissions After Hospitalization for Patients With Acute and Chronic Conditions in Toronto, Ontario, Canada
Authors: Shail Rawal, Jeevitha Srighanthan, Arthi Vasantharoopan, Hanxian Hu, George Tomlinson, Angela M. Cheung
Journal: JAMA (2019)

This study discusses observed associations between limited English proficiency, revisits, and readmissions to 2 Toronto hospitals.
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
Authors: Emilie Le Rhun, Jennifer Wallet, Audrey Mailliez, Marie Cecile Le Deley, Isabelle Rodrigues, Thomas Boulanger, Veronique Lorgis, Jerome Barrière, Yves Marie Robin, Michael Weller, Jacques Bonneterre
Journal: Neuro-Oncology (2019)

Abstract Background DEPOSEIN (NCT01645839) was a randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM), a common manifestation of breast cancer. Methods Patients with newly diagnosed LM defined by tumor cells in the cerebrospinal fluid or combination of clinical and neuroimaging signs of LM were randomized to receive systemic therapy alone (control group) or systemic therapy plus intrathecal liposomal cytarabine (experimental group). Progression-free survival related to LM (LM-PFS) was the primary endpoint. Results Thirty-seven and 36 patients were assigned to the control and the experimental groups. Median number of liposomal cytarabine injections in the experimental group was 5 (range 1–20). Focal radiotherapy was performed in 6 (16%) and 3 (8%) patients in the control and experimental groups. In the intent-to-treat population, median LM-PFS was 2.2 months (95% CI: 1.3–3.1) in the control versus 3.8 months (95% CI: 2.3–6.8) in the experimental group (hazard ratio 0.61, 95% CI: 0.38–0.98) (P = 0.04). Seventy-one patients have died. Median overall survival was 4.0 months (95% CI: 2.2–6.3) in the control versus 7.3 months (95% CI: 3.9–9.6) in the experimental group (hazard ratio 0.85, 95% CI: 0.53–1.36) (P = 0.51). Serious adverse events were reported in 22 and 30 patients, respectively. Quality of life until progression did not differ between groups. Conclusion The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and more active drugs may be required to demonstrate a survival benefit from intrathecal pharmacotherapy.
OA06.05 Evaluation of a Deep Learning-Based Automatic Classifier for the Classification of Perifissural Nodules
Authors: D. Han, M. Heuvelmans, M. Rook, M. Dorrius, L. Van Houten, N. Waterfield Price, L. Pickup, P. Novotny, J. Declerck, M. Oudkerk, P.m.a. Van Ooijen, F. Gleeson, R. Vliegenthart
Journal: Journal of Thoracic Oncology (2019)
EP1.14-45 ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
Authors: X. Li, C. Xu, S. Xu, W. Wang, J. Ye, Y. Zhu, T. Ge, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
P2.03-42 Highly Sensitive Sel-CapTM Lung Cancer Panel NGS for Detection of Tumor-Derived EGFR Mutations in Plasma Cell-Free DNA in Lung Cancer
Authors: J. Shin, J. Kim, M. Lee, M. Kim, H. Lee, H.K. Park, S.R. Kim, J. Kim, J.H. Kang
Journal: Journal of Thoracic Oncology (2019)
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
Authors: Suparna Wedam, Lola Fashoyin-Aje, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Laleh Amiri-Kordestani, Richard Pazdur, Julia A. Beaver
Journal: Clinical Cancer Research (2019)

Abstract On April 4, 2019, the FDA approved a supplemental new drug application for palbociclib (IBRANCE), to expand the approved indications in women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) in combination with an aromatase inhibitor or fulvestrant, to include men. Palbociclib was first approved in 2015 for use in combination with letrozole for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer as initial endocrine-based therapy in postmenopausal women and subsequently in 2016 in combination with fulvestrant in women with HR-positive, HER2-negative advanced breast cancer with disease progression following endocrine therapy. The current approval was primarily based on the results of the PALOMA-2 and PALOMA-3 trials and, supported by real-world data from electronic health records and insurance claims. To support the safety evaluation in male patients, data from two phase I studies with palbociclib and safety information from the global safety database, were also reviewed. This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or MBC.
Comparative efficacy of reduced or standard doses of lenograstim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation
Authors: M. Ozturk, F. Arpaci, S. Ataergin, A. Ozet, T. Cetin, O. Kuzhan, B. Ozturk, S. Kilic, S. Komurcu, T. Guler, B. Budakoglu
Journal: Journal of Clinical Oncology (2009)

7099 Background: 10 microg/kg/day of filgrastim and lenograstim have been recommended for mobilization of CD34+ cells without associated chemotherapy. However,in our previous randomized study we demonstrated that a 7.5 microg/kg/day dose of lenograstim has been as efficacious as 10 microg/kg/day of filgrastim. In this study, we investigated whether a reduced dose of lenograstim is equavalent to standard dose for autologous peripheral blood stem cell (PBSC) mobilization and transplantation. Methods: A total of 49 consecutive patients were randomized to either low dose (7.5 microg/kg/day, n = 24) or standard dose (10 microg/kg/day, n = 25) of lenograstim. These two groups were similar in regard to disease, sex, body weight, body surface area, conditioning regimens, previous chemotherapy cycles and radiotherapy. Each dose of lenograstim was administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In the posttransplant period, lenograstim was given at 5 microg/kg/day until leukocyte engraftment. Results: Successful mobilization with the first apheresis, was achieved in 10/24 (42%) patients in low dose group versus 14/25 (56%) patients in standard dose group. No significant difference was seen in the median number of CD34+cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the posttransplant period. Conclusions: Lenograstim 7.5 microg/kg/day is as efficious as Lenograstim 10 microg/kg/day for autologous PBSC mobilization and transplantation. No significant financial relationships to disclose.
The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.
Authors: Amy J. Johnson, Ryan Edwards, Lisa L. Smith, David M. Lucas, Carlo M. Croce, Natarajan Muthusamy, Ching-Shih Chen, Zhongfa Liu, Kenneth Chan, Michael R. Grever, John C. Byrd
Journal: Blood (2005)
Vaccines: poor access and fragmented healthcare could be behind falling uptake, says watchdog
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The abolition of primary care trusts in England as part of the 2012 Health and Social Care Act led to inconsistent delivery of the vaccination programme and may have contributed to the decline in preschool vaccination rates, the public spending watchdog has said.1

The National Audit Office’s report said that when NHS England took responsibility for commissioning vaccine call and recall in 2013 it didn’t set out the requirements of GPs. This meant that the way healthcare professionals reminded parents to vaccinate their children was inconsistent, it said.

The NAO said that some parents were finding it difficult to access vaccination services because of the “timing and availability of appointments” and that certain communities, such as Travellers, were being …
OA01.02 Endobronchial Ultrasound Staging of Operable NSCLC: Triple Negative Lymph Nodes May Not Require Routine Biopsy
Authors: D. Hylton, K. Selvakumaran, B. Kidane, J. Spicer, S. Turner, D. French, C. Wen, J. Masters, Y. Patel, J. Taylor, C. Finley, Y. Shargall, F. Farrokhyar, J. Agzarian, A. Seely, K. Yasufuku, W. Hanna
Journal: Journal of Thoracic Oncology (2019)
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis
Authors: Nashrawan Lababidi, Eric Ofosu Kissi, Walid A.M. Elgaher, Valentin Sigal, Jörg Haupenthal, Bianca C. Schwarz, Anna K.H. Hirsch, Thomas Rades, Marc Schneider
Journal: Journal of Controlled Release (2019)
Association Between Parental Income During Childhood and Risk of Schizophrenia Later in Life
Authors: Christian Hakulinen, Roger T. Webb, Carsten B. Pedersen, Esben Agerbo, Pearl L. H. Mok
Journal: JAMA Psychiatry (2019)

Evidence linking parental socioeconomic position and offspring's schizophrenia risk has been inconsistent, and how risk is associated with parental socioeconomic mobility has not been investigated.To elucidate the association between parental income level and income mobility during childhood and subsequent schizophrenia risk.National cohort study of all persons born in Denmark from January 1, 1980, to December 31, 2000, who were followed up from their 15th birthday until schizophrenia diagnosis, emigration, death, or December 31, 2016, whichever came first. Data analyses were from March 2018 to June 2019.Parental income, measured at birth year and at child ages 5, 10, and 15 years.Hazard ratios (HRs) for schizophrenia were estimated using Cox proportional hazard regression. Cumulative incidence values (absolute risks) were also calculated.The cohort included 1 051 033 participants, of whom 51.3% were male. Of the cohort members, 7544 (4124 [54.7%] male) were diagnosed with schizophrenia during 11.6 million person-years of follow-up. There was an inverse association between parental income level and subsequent schizophrenia risk, with children from lower income families having especially elevated risk. Estimates were attenuated, but risk gradients remained after adjustment for urbanization, parental mental disorders, parental educational levels, and number of changes in child-parent separation status. A dose-response association was observed with increasing amount of time spent in low-income conditions being linked with higher schizophrenia risk. Regardless of parental income level at birth, upward income mobility was associated with lower schizophrenia risk compared with downward mobility. For example, children who were born and remained in the lowest income quintile at age 15 years had a 4.12 (95% CI, 3.71-4.58) elevated risk compared with the reference group, those who were born in and remained in the most affluent quintile, but even a rise from the lowest income quintile at birth to second lowest at age 15 years appeared to lessen the risk elevation (HR, 2.80; 95% CI, 2.46-3.17). On the contrary, for those born in the most affluent quintile, downward income mobility between birth and age 15 years was associated with increased risks of developing schizophrenia.This study's findings suggest that parental income level and income mobility during childhood may be linked with schizophrenia risk. Although both causation and selection mechanisms could be involved, enabling upward income mobility could influence schizophrenia incidence at the population level.
P1.04-27 Processing Escapes: Novel Resistance Mechanisms Under Immune Checkpoint Inhibition in NSCLC
Authors: M. Wessolly, A. Streubel, R. Werner, S. Borchert, S. Stephan-Falkenau, S. Griff, E. Mairinger, J. Schmeller, R. Walter, T. Bauer, W. Eberhardt, T. Blum, K. Schmid, J. Kollmeier, F. Mairinger, T. Mairinger
Journal: Journal of Thoracic Oncology (2019)
P1.04-16 Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive
Authors: X. Mielgo Rubio, C. Aguado, M. Sereno, L.E. Chara, L. Cabezón, A. Velastegui, A. López, R. Lopez Castro, M. Sotelo, J. Rubio, J.A. Núñez, E. Pérez Fernández, C. Olier, J. De Castro Carpeno, M. Antoñanzas, S. Falagan, I. Gomez-Barreda, S. Custodio, P. Cruz
Journal: Journal of Thoracic Oncology (2019)